Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Abroad (travel likely)RecruitingPHASE3

Conditions

Kidney Diseases · Kidney Diseases, Chronic · Urological Diseases · Glomerulonephritis · Glomerular Disease · Glomerulonephritis, IGA · Glomerulopathy · Immunoglobulin Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Colorado Kidney Care Nephrology, Denver, Colorado, United States

    Contact: Principal Investigator (Laura Kooienga)
  • Nephrology Associates Of Central FL, Orlando, Florida, United States

    Contact: Principal Investigator (Arvind Madan)
  • NY Nephrology, Clifton Park, New York, United States

    Study coordinator · +1 518 579 0017
    Contact: Principal Investigator (Frank Cortazar)
  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Principal Investigator (Kristin Meliambro)
  • Knoxville Kidney Center Pllc, Brentwood, Tennessee, United States

    Contact: Principal Investigator (George Newman)
  • Dallas Renal Group, Dallas, Texas, United States

    Contact: Principal Investigator (Phuong Truong)
  • Dallas Renal Group, Dallas, Texas, United States

    Study coordinator · +1 214 697 7187
    Contact: Principal Investigator (Irfan Agha)
  • Nephro Asso North Illinois Indiana, Houston, Texas, United States

    Contact: Principal Investigator (Suneel Udani)
  • Novartis Investigative Site, Caba, Buenos Aires, Argentina

  • Novartis Investigative Site, La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site, Buenos Aires, Buenos Aires F.D., Argentina

  • Novartis Investigative Site, Catamarca, Catamarca Province, Argentina

  • Novartis Investigative Site, Santa Fe, Argentina

  • Novartis Investigative Site, Kogarah, New South Wales, Australia

  • Novartis Investigative Site, Toronto, Ontario, Canada

  • Novartis Investigative Site, Kuantan, Pahang, Malaysia

  • Novartis Investigative Site, Kuala Lumpur, Malaysia

  • Novartis Investigative Site, Cheonan, Chungcheongnam-do, South Korea

  • Novartis Investigative Site, Guri-si, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Seongnam-si, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Seoul, Seoul, South Korea

Study leads
  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals